Literature DB >> 12718906

Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors.

J P O'Rourke1, H Hiraragi, K Urban, M Patel, J C Olsen, B A Bunnell.   

Abstract

Skeletal muscle is an attractive target tissue for gene therapy involving both muscle and nonmuscle disorders. HIV-1-based vectors transduce mature skeletal muscle; however, the use of these vectors for human gene therapy may be limited by biosafety concerns. In this study, we investigated gene transfer using lentivirus vectors based on the equine infectious anemia virus (EIAV) in skeletal muscle in vitro and in vivo. EIAV vectors transduce proliferating and differentiating C2C12 mouse muscle cells; furthermore, the addition of the woodchuck hepatitis posttranscriptional element to EIAV vectors markedly increases gene expression in these cells. A single injection of EIAV vectors into skeletal muscle of adult mice led to detectable gene marking and gene expression for the duration of the 3-month study. Use of a second-generation EIAV self-inactivating vector (E-SIN) increased transduction in muscle cells in vitro, and injection of E-SIN vectors into skeletal muscle resulted in increased gene marking and gene expression compared to first-generation EIAV vectors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12718906     DOI: 10.1016/s1525-0016(03)00074-1

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  8 in total

1.  Restriction of feline immunodeficiency virus by Ref1, Lv1, and primate TRIM5alpha proteins.

Authors:  Dyana T Saenz; Wulin Teo; John C Olsen; Eric M Poeschla
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  [Comparison of several viral vectors for gene therapy of corneal endothelial cells].

Authors:  S C Beutelspacher; N Serbecic; P Tan; M O McClure
Journal:  Ophthalmologe       Date:  2005-12       Impact factor: 1.059

3.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

4.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

5.  Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.

Authors:  Jörg Zielonka; Ignacio G Bravo; Daniela Marino; Elea Conrad; Mario Perković; Marion Battenberg; Klaus Cichutek; Carsten Münk
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

6.  Retinal Gene Therapy: Current Progress and Future Prospects.

Authors:  Cristy A Ku; Mark E Pennesi
Journal:  Expert Rev Ophthalmol       Date:  2015-04-10

7.  LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives.

Authors:  Faisal A Al-Allaf; Charles Coutelle; Simon N Waddington; Anna L David; Richard Harbottle; Michael Themis
Journal:  Int Arch Med       Date:  2010-12-13

8.  Differential interaction between human and murine Crm1 and lentiviral Rev proteins.

Authors:  Yan Yue; Ayse K Coskun; Navneet Jawanda; Jim Auer; Richard E Sutton
Journal:  Virology       Date:  2017-10-10       Impact factor: 3.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.